<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01989325</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-520-216</org_study_id>
    <nct_id>NCT01989325</nct_id>
  </id_info>
  <brief_title>A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study during which patients with advanced multiple myeloma will receive
      either carfilzomib alone (single-agent) or carfilzomib in combination with investigational
      study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of
      both single-agent carfilzomib and carfilzomib + filanesib in treating myeloma. Patients will
      be allowed to crossover from single-agent carfilzomib to carfilzomib + filanesib if disease
      progression occurs. Approximately 75 patients from the US will be enrolled in this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the efficacy of both carfilzomib + study drug and single-agent carfilzomib in terms of progression-free survival.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the efficacy of both carfilzomib + study drug and single-agent carfilzomib in terms of objective response rate.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the safety of both carfilzomib + study drug and single-agent carfilzomib in terms of adverse events, clinical laboratory tests and electrocardiograms.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacokinetics (PK) of study drug, carfilzomib and a carfilzomib metabolite in patients treated with carfilzomib + study drug in terms of plasma concentration-time profiles and model-based PK parameters.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Following crossover from single-agent carfilzomib, assess the efficacy of carfilzomib + study drug in terms of objective response rate.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Following crossover from single-agent carfilzomib, assess the safety of carfilzomib + study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluate patient serum levels of alpha 1-acid glycoprotein (AAG) at Baseline and during the treatment period.</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Advanced Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Carfilzomib + Filanesib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single agent + Carfilzomib arm.
Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information.
Filgrastim to be administered per the approved product prescribing information and institutional guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carfilzomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single agent arm.
Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib, proteasome inhibitor; intravenous</intervention_name>
    <description>multiple dose, single schedule</description>
    <arm_group_label>Carfilzomib + Filanesib</arm_group_label>
    <arm_group_label>Carfilzomib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filanesib, KSP(Eg5) inhibitor; intravenous</intervention_name>
    <description>multiple dose, single schedule</description>
    <arm_group_label>Carfilzomib + Filanesib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone, steroid; oral or intravenous</intervention_name>
    <description>as indicated, per the carfilzomib prescribing information</description>
    <arm_group_label>Carfilzomib + Filanesib</arm_group_label>
    <arm_group_label>Carfilzomib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous</intervention_name>
    <description>standard of care</description>
    <arm_group_label>Carfilzomib + Filanesib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Confirmed multiple myeloma with measurable disease.

          -  Disease refractory to last myeloma regimen.

          -  Patients must have received at least 2 prior treatment regimens, including bortezomib
             and an IMiD (e.g., lenalidomide, thalidomide, pomalidomide). Induction therapy and
             stem cell transplant Â± maintenance are to be considered as a single regimen.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 within 14
             days prior to first dose of study treatment.

          -  Adequate hematology, liver and renal function laboratory values within 14 days prior
             to first dose of study treatment.

          -  Additional criteria exist.

        Key Exclusion Criteria:

          -  Prior treatment with carfilzomib, filanesib, or any other KSP inhibitor.

          -  Past or current plasma cell leukemia.

          -  Primary amyloidosis (amyloidosis associated with multiple myeloma is allowed).

          -  POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and
             skin changes).

          -  Ongoing Grade 3 or Grade 4 peripheral neuropathy, or Grade 2 peripheral neuropathy
             with pain despite appropriate interventions, within 28 days prior to first dose of
             study treatment.

          -  Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to
             first dose of study treatment.

          -  Concomitant malignancies or previous malignancies (other than multiple myeloma) with
             less than a 2-year disease-free interval at the time of first dose of study treatment.
             Patients with adequately resected basal or squamous cell carcinoma of the skin,
             carcinoma in situ of the cervix or breast, or Stage 1 prostate cancer are eligible
             irrespective of the time of diagnosis.

          -  Known pulmonary hypertension of any severity.

          -  Concurrent cardiac disease that, in the judgment of the Investigator, would make the
             patient inappropriate for study participation.

          -  Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B
             and/or hepatitis C.

          -  Acute active infection requiring treatment.

          -  Additional criteria exist.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Array BioPharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Genesis Cancer Center</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crescent City Research Consortium</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forrest General Cancer Center</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care - Blue Ash</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knight Cancer Institute at Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Lakes Health Care System</name>
      <address>
        <city>Watertown</city>
        <state>South Dakota</state>
        <zip>57201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center - UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WVU - Mary Babb Randolph Cancer Center</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2013</study_first_submitted>
  <study_first_submitted_qc>November 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2013</study_first_posted>
  <disposition_first_submitted>April 15, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 15, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 16, 2016</disposition_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Proteasome Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

